Skip to main content
Skip to footer

Dr. Hilde Vanaken

Industry Advisor, Lifesciences and Healthcare, TCS

For Roche, the COVID-19 scenario imposed an immediate threat having a detrimental impact on many of its ongoing and critical new clinical trials across different therapeutic areas. As a result, the team had to act fast to find a way to ensure business continuity of the impacted trials across all geographies. Read how Roche collaborated with TCS ADD team and implemented the TCS ADD Connected Clinical Trials (CCT)—eConsent solution to quickly rollout the digital informed consent. 

About the author

Dr. Hilde Vanaken
Dr Hilde is a passionate generalist with a track record of turning large & complex concepts into realization through collaboration. She joined TCS in 2019 as a Senior Industry Advisor for TCS Life Sciences & Healthcare having spent the previous +25 years at the pharma side where she shaped & led multiple cross-departmental & cross-pharma preclinical & clinical programs to success stories, e.g. Janssen’s Integrated Smart Trial & Engagement program, Transcelerate eConsent program.
Read more about authorRead more about author Read more about author